Availability, Accessibility, and Quality of Conservative Kidney Management Worldwide.


Journal

Clinical journal of the American Society of Nephrology : CJASN
ISSN: 1555-905X
Titre abrégé: Clin J Am Soc Nephrol
Pays: United States
ID NLM: 101271570

Informations de publication

Date de publication:
31 12 2020
Historique:
received: 08 06 2020
accepted: 28 10 2020
pubmed: 17 12 2020
medline: 15 12 2021
entrez: 16 12 2020
Statut: ppublish

Résumé

People with kidney failure typically receive KRT in the form of dialysis or transplantation. However, studies have suggested that not all patients with kidney failure are best suited for KRT. Additionally, KRT is costly and not always accessible in resource-restricted settings. Conservative kidney management is an alternate kidney failure therapy that focuses on symptom management, psychologic health, spiritual care, and family and social support. Despite the importance of conservative kidney management in kidney failure care, several barriers exist that affect its uptake and quality. The Global Kidney Health Atlas is an ongoing initiative of the International Society of Nephrology that aims to monitor and evaluate the status of global kidney care worldwide. This study reports on findings from the 2018 Global Kidney Health Atlas survey, specifically addressing the availability, accessibility, and quality of conservative kidney management. Respondents from 160 countries completed the survey, and 154 answered questions pertaining to conservative kidney management. Of these, 124 (81%) stated that conservative kidney management was available. Accessibility was low worldwide, particularly in low-income countries. Less than half of countries utilized multidisciplinary teams (46%); utilized shared decision making (32%); or provided psychologic, cultural, or spiritual support (36%). One-quarter provided relevant health care providers with training on conservative kidney management delivery. Overall, conservative kidney management is available in most countries; however, it is not optimally accessible or of the highest quality.

Sections du résumé

BACKGROUND AND OBJECTIVES
People with kidney failure typically receive KRT in the form of dialysis or transplantation. However, studies have suggested that not all patients with kidney failure are best suited for KRT. Additionally, KRT is costly and not always accessible in resource-restricted settings. Conservative kidney management is an alternate kidney failure therapy that focuses on symptom management, psychologic health, spiritual care, and family and social support. Despite the importance of conservative kidney management in kidney failure care, several barriers exist that affect its uptake and quality.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS
The Global Kidney Health Atlas is an ongoing initiative of the International Society of Nephrology that aims to monitor and evaluate the status of global kidney care worldwide. This study reports on findings from the 2018 Global Kidney Health Atlas survey, specifically addressing the availability, accessibility, and quality of conservative kidney management.
RESULTS
Respondents from 160 countries completed the survey, and 154 answered questions pertaining to conservative kidney management. Of these, 124 (81%) stated that conservative kidney management was available. Accessibility was low worldwide, particularly in low-income countries. Less than half of countries utilized multidisciplinary teams (46%); utilized shared decision making (32%); or provided psychologic, cultural, or spiritual support (36%). One-quarter provided relevant health care providers with training on conservative kidney management delivery.
CONCLUSIONS
Overall, conservative kidney management is available in most countries; however, it is not optimally accessible or of the highest quality.

Identifiants

pubmed: 33323461
pii: 01277230-202101000-00012
doi: 10.2215/CJN.09070620
pmc: PMC7792657
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

79-87

Informations de copyright

Copyright © 2021 by the American Society of Nephrology.

Références

Anand S, Kurella Tamura M, Chertow GM: The elderly patients on hemodialysis. Minerva Urol Nefrol 62: 87–101, 2010
Davison SN, Levin A, Moss AH, Jha V, Brown EA, Brennan F, Murtagh FE, Naicker S, Germain MJ, O’Donoghue DJ, Morton RL, Obrador GT; Kidney Disease Improving Global Outcomes: Executive summary of the Kidney Disease Improving Global Outcomes controversies conference on supportive care in chronic kidney disease: Developing a roadmap to improving quality care. Available at: https://kdigo.org/ . Kidney Int 88: 447–459, 2015 25923985
Brown MA, Crail SM, Masterson R, Foote C, Robins J, Katz I, Josland E, Brennan F, Stallworthy EJ, Siva B, Miller C, Urban AK, Sajiv C, Glavish RN, May S, Langham R, Walker R, Fassett RG, Morton RL, Stewart C, Phipps L, Healy H, Berquier I: ANZSN renal supportive care 2013: Opinion pieces [corrected] [published correction appears in Nephrology (Carlton) 19: 175, 2014]. Nephrology (Carlton) 18: 401–454, 2013 23586687
Davison SN, Tupala B, Wasylynuk BA, Siu V, Sinnarajah A, Triscott J: Recommendations for the care of patients receiving conservative kidney management: Focus on management of CKD and symptoms. Clin J Am Soc Nephrol 14: 626–634, 2019 30819670
Ladin K, Pandya R, Kannam A, Loke R, Oskoui T, Perrone RD, Meyer KB, Weiner DE, Wong JB: Discussing conservative management with older patients with CKD: An interview study of nephrologists. Am J Kidney Dis 71: 627–635, 2018 29396240
Grubbs V, Tuot DS, Powe NR, O’Donoghue D, Chesla CA: System-level barriers and facilitators for foregoing or withdrawing dialysis: A qualitative study of nephrologists in the United States and England. Am J Kidney Dis 70: 602–610, 2017 28242134
Bello AK, Levin A, Lunney M, Osman MA, Ye F, Ashuntantang GE, Bellorin-Font E, Benghanem Gharbi M, Davison SN, Ghnaimat M, Harden P, Htay H, Jha V, Kalantar-Zadeh K, Kerr PG, Klarenbach S, Kovesdy CP, Luyckx VA, Neuen BL, O’Donoghue D, Ossareh S, Perl J, Rashid HU, Rondeau E, See E, Saad S, Sola L, Tchokhonelidze I, Tesar V, Tungsanga K, Turan Kazancioglu R, Wang AY, Wiebe N, Yang CW, Zemchenkov A, Zhao MH, Jager KJ, Caskey F, Perkovic V, Jindal KK, Okpechi IG, Tonelli M, Feehally J, Harris DC, Johnson DW: Status of care for end stage kidney disease in countries and regions worldwide: International cross sectional survey. BMJ 367: l5873, 2019 31672760
Bello AK, Johnson DW, Feehally J, Harris D, Jindal K, Lunney M, Okpechi IG, Salako BL, Wiebe N, Ye F, Tonelli M, Levin A: Global Kidney Health Atlas (GKHA): Design and methods. Kidney Int Suppl (2011) 7: 145–153, 2017 30675429
Bello AK, Levin A, Tonelli M, Okpechi IG, Feehally J, Harris D, Jindal K, Salako BL, Rateb A, Osman MA, Qarni B, Saad S, Lunney M, Wiebe N, Ye F, Johnson DW: Assessment of global kidney health care status. JAMA 317: 1864–1881, 2017 28430830
International Society of Nephrology: Global Kidney Health Atlas. Available at: https://www.theisn.org/in-action/research/global-kidney-health-atlas/ . Accessed August 26, 2019
International Society of Nephrology: Regional Boards. Available at: https://www.theisn.org/about-isn/governance/regional-boards/ . Accessed February 14, 2020
Murtagh FE, Burns A, Moranne O, Morton RL, Naicker S: Supportive care: Comprehensive conservative care in end-stage kidney disease. Clin J Am Soc Nephrol 11: 1909–1914, 2016 27510453
National Institute for Health and Care Excellence: Renal replacement therapy and conservative management. NICE guideline [NG107], 2018. Available at: https://www.nice.org.uk/guidance/ng107 . Accessed September 17, 2019
Harrison TG, Tam-Tham H, Hemmelgarn BR, James MT, Sinnarajah A, Thomas CM: Identification and prioritization of quality indicators for conservative kidney management. Am J Kidney Dis 73: 174–183, 2019 30482578
University of Bristol: Prepare for kidney care trial. Available at: http://www.bristol.ac.uk/population-health-sciences/projects/prepare-kc-trial/ . Accessed September 17, 2019
Alberta Health Services: Conservative Kidney Management (CKM), 2016. Available at: https://www.ckmcare.com . Accessed September 17, 2019
Fortnum D, Smolonogov T, Walker R, Kairaitis L, Pugh D: ‘My kidneys, my choice, decision aid’: Supporting shared decision making. J Ren Care 41: 81–87, 2015 25491064
Davis JL, Davison SN: Hard choices, better outcomes: A review of shared decision-making and patient decision aids around dialysis initiation and conservative kidney management. Curr Opin Nephrol Hypertens 26: 205–213, 2017 28212179
St. George and Sutherland Hospitals, Renal Department: Information for patients about advanced kidney disease: Dialysis and non-dialysis treatments, 2017. Available at: https://stgrenal.org.au/sites/default/files/upload/Predialysis/Patient information about dialysis 2018_V2.pdf. Accessed February 15, 2020
Harris DCH, Davies SJ, Finkelstein FO, Jha V, Donner JA, Abraham G, Bello AK, Caskey FJ, Garcia GG, Harden P, Hemmelgarn B, Johnson DW, Levin NW, Luyckx VA, Martin DE, McCulloch MI, Moosa MR, O’Connell PJ, Okpechi IG, Pecoits Filho R, Shah KD, Sola L, Swanepoel C, Tonelli M, Twahir A, van Biesen W, Varghese C, Yang CW, Zuniga C; Working Groups of the International Society of Nephrology’s 2nd Global Kidney Health Summit: Increasing access to integrated ESKD care as part of universal health coverage. Kidney Int 95: S1–S33, 2019 30904051
Hole B, Hemmelgarn B, Brown E, Brown M, McCulloch MI, Zuniga C, Andreoli SP, Blake PG, Couchoud C, Cueto-Manzano AM, Dreyer G, Garcia G, Jager KJ, McKnight M, Morton RL, Murtagh FEM, Naicker S, Obrador GT, Perl J, Rahman M, Shah KD, Van Biesen W, Walker RC, Yeates K, Zemchenkov A, Zhao MH, Davies SJ, Caskey FJ: Supportive care for end-stage kidney disease: An integral part of kidney services across a range of income settings around the world. Kidney Int Suppl (2011) 10: e86–e94, 2020 32149013

Auteurs

Meaghan Lunney (M)

Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.

Aminu K Bello (AK)

Division of Nephrology and Immunology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.

Adeera Levin (A)

Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Helen Tam-Tham (H)

Department of Medicine, University of Calgary, Calgary, Alberta, Canada.

Chandra Thomas (C)

Department of Medicine, University of Calgary, Calgary, Alberta, Canada.

Mohamed A Osman (MA)

Department of Family Medicine, University of Ottawa, Ottawa, Ontario, Canada.

Feng Ye (F)

Division of Nephrology and Immunology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.

Ezequiel Bellorin-Font (E)

Division of Nephology and Hypertension, Saint Louis University, St. Louis, Missouri.

Mohammed Benghanem Gharbi (M)

Urinary Tract Diseases Department, Faculty of Medicine and Pharmacy of Casablanca, University Hassan II of Casablanca, Casablanca, Morocco.

Mohammad Ghnaimat (M)

Nephrology Division, Department of Internal Medicine, The Specialty Hospital, Amman, Jordan.

Htay Htay (H)

Department of Renal Medicine, Singapore General Hospital, Singapore.

Yeoungjee Cho (Y)

Australasian Kidney Trials Network, University of Queensland, Brisbane, Queensland, Australia.
Translational Research Institute, Brisbane, Queensland, Australia.
Metro South Integrated Nephrology and Transplant Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Vivekanand Jha (V)

George Institute for Global Health, University of New South Wales, New Delhi, India.
Department of Epidemiology and Biostatistics, School of Public Health, Imperial College, London, United Kingdom.
Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, Karnataka, India.

Shahrzad Ossareh (S)

Division of Nephrology, Department of Medicine, Hasheminejad Kidney Center, Iran University of Medical Sciences, Tehran, Iran.

Eric Rondeau (E)

Intensive Care Nephrology and Transplantation Department, Hopital Tenon, Assistance Publique-Hopitaux de Paris, Paris, France.
Intensive Care Nephrology and Transplantation Department, Hopital Tenon, Assistance Publique-Hopitaux de Paris, Paris, France and Sorbonne Université, Paris, France.

Laura Sola (L)

Dialysis Unit, Centro de Asistencia del Sindicato Médico del Uruguay - Institución de Asistencia Medica Privada de Profesionales (CASMU-IAMPP), Montevideo, Uruguay.

Irma Tchokhonelidze (I)

Nephrology Development Clinical Center, Tbilisi State Medical University, Tbilisi, Georgia.

Vladimir Tesar (V)

Department of Nephrology, General University Hospital, Charles University, Prague, Czech Republic.

Kriang Tungsanga (K)

Department of Medicine, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand.
Division of Nephrology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Bhumirajanagarindra Kidney Institute, Bangkok, Thailand.

Rumeyza Turan Kazancioglu (RT)

Division of Nephrology, Bezmialem Vakif University, Istanbul, Turkey.

Angela Yee-Moon Wang (AY)

Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, China.

Chih-Wei Yang (CW)

Kidney Research Center, Department of Nephrology, Chang Gung Memorial Hospital, Linkou, Taiwan.
Kidney Research Center, Department of Nephrology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.

Alexander Zemchenkov (A)

Department of Internal Diseases, Clinical Pharmacology, and Nephrology, North-Western State Medical University named after I. I. Mechnikov, St. Petersburg, Russia.
Department of Nephrology and Dialysis, Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia.

Ming-Hui Zhao (MH)

Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China.
Key Lab of Renal Disease, Ministry of Health of China, Beijing, China.
Key Lab of Chronic Kidney Disease Prevention and Treatment, Ministry of Education of China, Beijing, China.
Peking-Tsinghua Center for Life Sciences, Beijing, China.

Kitty J Jager (KJ)

European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Registry, Department of Medical Informatics, Academic Medical Center, Amsterdam Public Health Research Institute, University of Amsterdam, Amsterdam, The Netherlands.

Kailash K Jindal (KK)

Division of Nephrology and Immunology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.

Ikechi G Okpechi (IG)

Division of Nephrology and Hypertension, University of Cape Town, Cape Town, South Africa.
Kidney and Hypertension Research Unit, University of Cape Town, Cape Town, South Africa.

Edwina A Brown (EA)

Imperial College Renal and Transplant Centre, Hammersmith Hospital, London, England.

Mark Brown (M)

Department of Renal Medicine, St George Hospital and University of New South Wales, Sydney, New South Wales, Australia.

Marcello Tonelli (M)

Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
Pan-American Health Organization/World Health Organization's Collaborating Centre in Prevention and Control of Chronic Kidney Disease, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

David C Harris (DC)

Centre for Transplantation and Renal Research, Westmead Institute for Medical Research, University of Sydney, Sydney, New South Wales, Australia.

David W Johnson (DW)

Australasian Kidney Trials Network, University of Queensland, Brisbane, Queensland, Australia.
Translational Research Institute, Brisbane, Queensland, Australia.
Metro South Integrated Nephrology and Transplant Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Fergus J Caskey (FJ)

UK Renal Registry, Learning and Research, Southmead Hospital, Bristol, United Kingdom and Population Health Sciences, University of Bristol, Bristol, United Kingdom.
Richard Bright Renal Unit, Southmead Hospital, North Bristol National Health Service Trust, Bristol, United Kingdom.

Sara N Davison (SN)

Division of Nephrology and Immunology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH